NEKTAR THERAPEUTICS - 8-K Filing
Nektar Therapeutics reported first-quarter 2026 financial results on May 7, 2026. The company had $731.6 million in cash and investments as of March 31, 2026, up from $245.8 million at the end of Q4 2025; this excludes proceeds from a secondary offering completed on April 23, 2026. Revenue was $10.9 million for the quarter compared to $10.5 million in Q1 2025. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $NKTR